Push-pull osmotic pump for zero order delivery of lithium carbonate: Development and in vitro characterization

被引:7
作者
Patel, Vineetkumar [1 ]
Chudasama, Arpan [1 ]
Nivsarkar, Manish [2 ]
Vasu, Kamala [3 ]
Shishoo, Chamanlal [1 ]
机构
[1] BV Patel PERD Ctr, Dept Pharmaceut, Ahmadabad 380054, Gujarat, India
[2] BV Patel PERD Ctr, Dept Pharmacol & Toxicol, Ahmadabad 380054, Gujarat, India
[3] BV Patel PERD Ctr, Dept Med Chem, Ahmadabad 380054, Gujarat, India
关键词
Lithium carbonate (LC); push-pull osmotic pump (PPOP); 24 hours zero order release; type III dissolution apparatus; laser drill; DRUG-DELIVERY; PHARMACOKINETICS; RELEASE;
D O I
10.3109/10837450.2010.542577
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lithium carbonate, a drug with narrow therapeutic index, needs therapeutic drug monitoring and dose adjustment to maintain lithium level within the therapeutic window. Conventional formulations of lithium carbonate exhibit immediate drug release causing swing/fluctuations in the plasma concentration of lithium, consequently leading to unfavorable side-effects and make dose adjustment difficult. The push-pull osmotic pump has been developed for zero order delivery of lithium carbonate for a period of 24 h. The effect of various formulation variables on bilayer core tablet and its semi permeable coating along with orifice diameter have been investigated and optimized for desired drug release profile. Drug release was found to be inversely proportional to the membrane thickness but directly related to the amount of pore formers in the semipermeable membrane. Images from a scanning electron microscope confirmed the presence of pores in the semipermeable membrane which facilitated the required water penetration. No distortion or change in orifice shape was noticed prior to and after the dissolution study. Drug release from the developed formulation was found to be independent of pH, agitation intensity and agitation mode but depended on osmotic pressure of dissolution media.
引用
收藏
页码:375 / 382
页数:8
相关论文
共 25 条
[1]   SERUM LEVEL MONITORING AND CLINICAL PHARMACOKINETICS OF LITHIUM [J].
AMDISEN, A .
CLINICAL PHARMACOKINETICS, 1977, 2 (02) :73-92
[2]  
Baldessarini RJ., 2001, Goodman Gilman's The pharmacological basis of therapeutics, P485, DOI DOI 10.1002/hup.540
[3]   The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse. [J].
Bowden C.L. .
Current Psychiatry Reports, 2000, 2 (6) :490-494
[4]   Modeling and comparison of dissolution profiles [J].
Costa, P ;
Manuel, J ;
Lobo, S .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 13 (02) :123-133
[5]  
Geerke JH, Patent No. [5,658,474, 5658474]
[8]  
Langer R, 1998, NATURE, V392, P5
[9]   Effects of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets [J].
Late, Sameer G. ;
Yu, Yi-Ying ;
Banga, Ajay K. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2009, 365 (1-2) :4-11
[10]  
Moore J.W., 1996, PHARM TECHNOLOGIES, V20, P64, DOI DOI 10.1017/CCOL521633230.011